Article

Metabolic activation stimulates acid secretion and expression of matrix degrading proteases in human osteoblasts

Otto-von-Guericke-Universität Magdeburg, Magdeburg, Saxony-Anhalt, Germany
Annals of the Rheumatic Diseases (Impact Factor: 9.27). 02/2004; 63(1):67-70. DOI: 10.1136/ard.2002.005256
Source: PubMed

ABSTRACT Both cellular and matrix components of healthy bone are permanently renewed in a balanced homoeostasis. Osteoclastic bone resorption involves the expression of vacuolar-type ATPase proton pumps (vATPase) on the outer cell membrane and the secretion of matrix degrading proteases. Osteoblasts modulate the deposition of bone mineral components and secrete extracellular matrix proteins.
To investigate the ability of osteoblasts and osteosarcoma to secrete acid and express matrix degrading proteases upon metabolic activation. To examine also the potential contribution of vATPases to proton secretion expressed on osteoblasts.
Osteoblasts were isolated from trabecular bone and characterised by reverse transcriptase-polymerase chain reaction and immunohistochemistry. Proton secretion was analysed by a cytosensor microphysiometer.
Osteoblasts not only express matrix degrading proteases upon stimulation with tumour necrosis factor or with phorbol ester but they also secrete protons upon activation. Proton secretion by osteoblasts is associated partially with proton pump ATPases.
These data suggest that, in addition to monocyte derived osteoclasts, cytokine activated mesenchymal osteoblasts and osteosarcoma cells may contribute to the acidic milieu required for bone degradation.

0 Bookmarks
 · 
84 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Die juvenile Dermatomyositis ist eine idiopathische entzndliche Multisystemerkrankung, charakterisiert durch eine chronische Entzndung der Skelettmuskulatur mit kutanen und vaskulitischen Manifestationen. Die Behandlung mit Kortikosteroiden und Immunsuppressiva stellt einen aktuellen Standard dar. Die Verfgbarkeit einer spezifischen antientzndlichen Intervention mit Biologika und die Toxizitt der konventionellen Therapie lassen Behandlungsversuche mit Ersteren, insbesondere bei therapierefraktren Verlufen, als sinnvoll erscheinen. Dabei sind v.a. Inhibitoren des proinflammatorischen Zytokins Tumornekrosefaktor , Etanercept und Infliximab, und der B-Zell-depletierende Antikrper Rituximab eingesetzt worden. In dieser bersicht sollen die derzeitigen Therapieerfahrungen dargestellt werden.Juvenile dermatomyositis is an idiopathic, inflammatory, multi-systemic disease characterized by a chronic inflammation of skeletal muscles with cutaneous and vasculitic manifestations. Treatment with corticosteroids and immunosuppressants has become standard. The availability of specific anti-inflammatory biological agents and the toxicity of conventional therapy have led to therapeutic trials using such agents, especially in refractory disease. Inhibitors of the proinflammatory cytokine tumour necrosis factor-, etanercept and infliximab, and the B-cell depleting antibody rituximab have been used. In this report, our current knowledge of treatment of juvenile dermatomyositis using biologicals is reviewed.
    Monatsschrift Kinderheilkunde 02/2007; 155(2):111-117. DOI:10.1007/s00112-006-1453-x · 0.28 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cathepsin K (CatK) is a lysosomal protease with collagenolytic activity, and its secretion by osteoclasts is responsible for degrading organic bone matrix. People with pathologic bone resorption have higher circulating CatK concentrations. Canine osteosarcoma (OS) cells will possess CatK, and its secretion will be cytokine inducible. Circulating CatK concentrations will be increased in dogs with OS, and will be a surrogate marker of bone resorption. Fifty-one dogs with appendicular OS and 18 age- and weight-matched healthy control dogs. In a prospective study, expressions of CatK mRNA and protein were investigated in OS cells. The inducible secretion and proteolytic activity of CatK from OS cells was assessed in vitro. Serum CatK concentrations were quantified in normal dogs and dogs with OS and its utility as a bone resorption marker was evaluated in dogs with OS treated with palliative radiation and antiresorptive agents. Canine OS cells contain preformed CatK within cytoplasmic vesicles. In OS cells, TGFβ1 induced the secretion of CatK, which degraded bone-derived type I collagen in vitro. CatK concentrations were higher in dogs with OS than healthy dogs (11.3 ± 5.2 pmol/L versus 8.1 ± 5.0 pmol/L, P = .03). In a subset of dogs with OS, pretreatment CatK concentrations gradually decreased after palliative radiation and antiresorptive treatment, from 9.3 ± 3.2 pmol/L to 5.0 ± 3.1 pmol/L, P = .03. Canine OS is associated with pathologic bone resorption, and CatK inhibitors might aid in the management of canine OS-related malignant osteolysis.
    Journal of Veterinary Internal Medicine 12/2011; 26(1):126-34. DOI:10.1111/j.1939-1676.2011.00834.x · 2.06 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Aminopeptidases (APs) are enzymes involved in a wide variety of biological processes and present in a variety of different cell populations. The authors studied these enzymes in primary cultured human osteoblasts in order to establish an activity profile and thereby contribute to knowledge of bone tissue. The authors used 13 different substrates (N-terminal amino acids) and a fluorimetric assay to examine AP activity associated with the membranes of cultured osteoblasts. The authors demonstrated activity > 10 pmol/min/10(4) cells when glycine, alanine, leucine, arginine, phenylalanine, methionine, and lysine were used as substrates. The activity was markedly lower (<1.6 pmol/min/10(4) cells) when the other N-terminal amino acids were used. Puromycin and bestatin inhibited AP activity, though not completely, when we used AlaNA or LeuNA as substrates. Further studies are warranted to determine the role of these enzymes in bone tissue physiology.
    Biological Research for Nursing 07/2011; 15(1). DOI:10.1177/1099800411414870 · 1.34 Impact Factor

Full-text (2 Sources)

Download
16 Downloads
Available from
Jun 4, 2014